Ethyreal Bio
Dedicated to improving the lives of people with Thyroid Eye Disease and Graves' Disease
San Francisco, United States · Founded 2024 · $101.0M raised
- Headquarters
- San Francisco, Massachusetts
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- ethyrealbio.com
- Total Funding
- $101.0M
- Last Round
- $101.0M SeedJun 2026
- Rounds
- 2
About
Ethyreal Bio is a Cambridge, Massachusetts-based biotechnology company developing precision therapies targeting the thyroid-stimulating hormone receptor (TSHR). Its lead asset, ETHY-001, is a potentially best-in-class anti-TSHR antibody designed to address the root cause of both Graves disease and thyroid eye disease, with clinical studies planned for late 2026.
Summary
Ethyreal Bio is a Biotech company based in San Francisco, United States, founded in 2024. It has raised $101.0M in total across 2 rounds, most recently a $101.0M Seed round in Jun 2026.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...